📰 Nasdaq Arqt News
Nasdaq Arqt News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Arqt. Real-time updates on events, politics, business and more.
April 12, 2024
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among […]
April 5, 2024
WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company...
March 23, 2024
Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) were down 4.6% during trading on Thursday . The stock traded as low as $10.17 and last traded at $10.30. Approximately 1,029,580 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 5,305,673 shares. The stock had previously closed […]
March 11, 2024
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report)’s stock price was down 7.7% during mid-day trading on Monday . The company traded as low as $10.06 and last traded at $10.29. Approximately 1,248,266 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 5,378,077 shares. The stock had previously […]
March 10, 2024
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement ...
February 28, 2024
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) issued its earnings results on Tuesday. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.08), MarketWatch Earnings reports. Arcutis Biotherapeutics had a negative return on equity of 224.85% and a negative net margin of 546.23%. The business had revenue […]
February 28, 2024
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.08), MarketWatch Earnings reports. The firm had revenue of $13.53 million for the quarter, compared to the consensus estimate of $11.78 million. Arcutis Biotherapeutics had […]
February 17, 2024
E Fund Management Co. Ltd. trimmed its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 19.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 21,535 shares of the company’s stock after selling 5,342 shares during the quarter. E Fund Management […]
February 15, 2024
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 16,780,000 shares, a drop of 19.4% from the January 15th total of 20,830,000 shares. Based on an average trading volume of 5,340,000 shares, the days-to-cover ratio […]
January 30, 2024
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) shot up 2.8% on Tuesday . The company traded as high as $6.26 and last traded at $6.23. 631,670 shares traded hands during trading, a decline of 89% from the average session volume of 5,630,610 shares. The stock had previously closed at $6.06. Analysts Set New Price […]